Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|May 14, 2026
Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitorsRahul Mudumba, Xiaofan Liu, Shihan Jin, et al.Frontiers in Public Health|February 6, 2023
Characterization of mortality and high-risk characteristics of thyroid cancer in Filipinos using the California Cancer RegistryRobert Hsu, Kai-Ya Tsai, Krithika Chennapan, et al.Seminars in Thoracic and Cardiovascular Surgery|June 21, 2019
Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung CancerJason C Ye, Li Ding, Scott M Atay, et al.Cancer Treatment and Research Communications|August 23, 2023
Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancerMadeline MacDonald, Darin Poei, Alexis Leyba, et al.Oncology and Therapy|November 9, 2025
Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib MonotherapyJorge J Nieva, Xuejun Wang, Deborah Doroshow, et al.Journal of Medical Economics|April 13, 2026
Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancerGilberto de Lima Lopes, Harry Freeman, Emily Procter, et al.JTO Clinical and Research Reports|April 24, 2023
Biopsy Method and Needle Size on Success of Next-Generation Sequencing in NSCLC: A Brief ReportRaymond Diep, Madeline MacDonald, Ryan Cooper, et al.Cancers|March 28, 2024
Characterization of Thyroid Cancer among Hispanics in California, USA, from 2010 to 2020Robert C Hsu, Kai-Ya Tsai, David J Benjamin, et al.Therapeutic Advances in Medical Oncology|March 5, 2026
Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitorsRobert Hsu, Karen Resnick, Peter Zang, et al.Oncology|May 11, 2012
A pilot study of long-acting octreotide for symptomatic malignant ascitesAminah Jatoi, Jorge J Nieva, Rui Qin, et al.Pageof 5